The alliance has completed projects for companies around the globe since it was established in 2017
Rentschler Biopharma and Leukocare are celebrating the fourth anniversary of their strategic alliance. Established in 2017 and recently expanded into the US, the alliance is designed to integrate tailored formulation development into the manufacturing process and help to address the challenges of increasingly complex biopharmaceuticals. Clients benefit from this alliance, the companies say, through shorter development timelines, cost savings and potentially additional patent protection.
During these four years, the alliance has completed projects for companies around the globe, ranging from established monoclonal antibodies to multispecific formats, as well as novel enzymes and scaffolds. They include both early- and late-stage development programs.
Formulation development projects within the alliance have included adjustment of existing formulations and creation of novel formulations for improving stability or extension of storage time at room temperature.
With the recent opening of Leukocare’s US development labs and offices at Rentschler Biopharma's facility in the Greater Boston area, the two companies will work together closely in the US as well as in Europe.
Dr Frank Mathias, CEO of Rentschler Biopharma, said: “Our strategic alliance with Leukocare is a great success for our two companies and, importantly, for our clients. Formulation issues often lead to the failure of drug development projects or significant delays both in early and late clinical stage, making formulation a critical success factor. Drug development and formulation need to cooperate, and, together, our two companies can address client needs in early- or late-stage development, as well as in commercial manufacturing optimisation. We are delighted that this alliance now has a solid footprint in both Europe and the U.S.”
Michael Scholl, CEO of Leukocare, said: “Both of our companies are highly focused on not just meeting but exceeding client expectations. Already four years ago, we recognized an increasing demand for advanced and accelerated formulation development services combined with excellent CDMO services. We are excited to expand our presence into the U.S., enabling us to work closely with Rentschler Biopharma on both sides of the Atlantic to provide optimal solutions and customised services for each joint project. We very much look forward to continuing this strong and highly fruitful partnership.”